The role of BRAF V600 mutation in melanoma - Wikidata - awgldk - TriplyDB

The role of BRAF V600 mutation in melanoma

The role of BRAF V600 mutation in melanoma

http://www.wikidata.org/entity/Q34637951

about

MLK3 Signaling in Cancer Invasion Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic Melanoma Tailoring the Treatment of Melanoma: Implications for Personalized Medicine Molecular landscape of pancreatic cancer: implications for current clinical trials The GIST of targeted therapy for malignant melanoma Emerging targeted therapies for melanoma treatment (review)Delayed access to treatments for rare diseases: who's to blame?Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma Systemic Therapies for Late-stage Melanoma Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer A protein deep sequencing evaluation of metastatic melanoma tissues Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer mutLBSgeneDB: mutated ligand binding site gene DataBase.MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.Combined dabrafenib and trametinib treatment in a case of chemotherapy-refractory extrahepatic BRAF V600E mutant cholangiocarcinoma: dramatic clinical and radiological response with a confusing synchronic new liver lesion Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling Histone deacetylase inhibitor-temozolomide co-treatment inhibits melanoma growth through suppression of Chemokine (C-C motif) ligand 2-driven signals.BRAF(V600E) melanoma cells secrete factors that activate stromal fibroblasts and enhance tumourigenicity.Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site.Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy Genetic pathways, prevention, and treatment of sporadic colorectal cancer Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis Melanoma: Molecular Pathogenesis and Therapeutic Management BRAF gene: From human cancers to developmental syndromes.HMMvar-func: a new method for predicting the functional outcome of genetic variants.The immune-related role of BRAF in melanoma.Novel rapid liquid chromatography tandem masspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state.The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options.Aberrant DNA Methylation in Keratoacanthoma.Small RNA deep sequencing discriminates subsets of extracellular vesicles released by melanoma cells--Evidence of unique microRNA cargos.Multiplying therapies and reducing toxicity in metastatic melanoma.Sunrise in melanoma management: Time to focus on melanoma burden in Asia.Interferon-γ-induced activation of Signal Transducer and Activator of Transcription 1 (STAT1) up-regulates the tumor suppressing microRNA-29 family in melanoma cells.(13)C MRS and LC-MS Flux Analysis of Tumor Intermediary Metabolism.miR-579-3p controls melanoma progression and resistance to target therapy.

P2860

Q26746892-7F1FA780-5A4E-4831-BA00-A9EDA16634DF Q26771941-38A36E9E-DE59-4075-8D61-D2B164C6B40D Q26775806-789B3BA4-DC63-47FB-A385-A20A6F32B010 Q26824528-3AE11CB8-E9C7-49CB-B01A-5A472EA0CEF5 Q26827092-20D833A3-F716-4F99-9A2A-EF339435E047 Q26829997-04C922FA-C303-4207-973D-8D760676426D Q26864797-09692D1F-7842-447C-A58C-27A592336C6F Q27851927-6960F192-6747-4C54-ABFF-856C0FDD722D Q28080215-D8AF49E7-F265-4B8A-904B-66E5615C6AF7 Q28084216-5CB17876-2000-47E5-A642-4B664F33A2E3 Q28546229-3ECDCD29-F19E-4478-BC48-88B5D3450351 Q28551002-DDEEB18B-2FE9-4F5C-952B-BECE67267B6A Q30395862-7C33B8E4-BC7B-439F-90D3-47C0B8BC5BC6 Q31012806-D33B28B7-CA47-455A-A1CB-7B8A51FF62E8 Q33435672-085E9F6B-0659-4628-A0DF-C8AE432AF70D Q33593231-0CD5AA57-8984-4FBE-B30B-7E3A5DD5AAB2 Q33605879-A5FD24A8-1579-488E-9A91-80A0194789A9 Q33653672-3F0B85FA-F5B4-498C-A039-0106E236FDA5 Q33665825-7225CA46-D304-4A4E-8A12-7D2C32BBAF6B Q33667485-87D047AF-1C04-41AA-B3C2-D7821AD105A8 Q33718695-3178C072-724B-487D-A55E-34E871B8AA14 Q34101036-A877A132-1B7A-4716-975C-482322706008 Q34354569-BB62EF35-148D-428E-B3F6-BA82084A7A66 Q34446657-D19FAE8F-F4CA-49A7-A4E6-B67C837FBC2B Q34671658-BFA600BF-9B23-46F7-B5A8-DE59EDBE2887 Q34832690-D1F54D3B-14D9-4151-B270-C29B65098E76 Q34903217-36A60883-566F-467A-B9FD-4BB94F97A764 Q35137163-08D79F2D-51FA-4B43-8620-FBE539FD24E4 Q35802430-3FCE1C6B-629C-4A1A-940B-B15E6329D59C Q35827746-3D103F8F-D193-4E2E-9DC6-545440BB67F7 Q35847321-195261D6-99AB-496F-8691-61467B95491B Q35872991-377A13E4-1DDC-472F-A2FB-A7ABAF7F8539 Q36102807-7C167C9B-2E32-4794-BF78-8EC8BE061C36 Q36176290-CFD54262-D019-4A5B-8A12-D0920ABDD457 Q36191656-0D3054C4-3480-45D2-9059-05A2370228F8 Q36216263-C90F287B-97EF-403D-8913-4A06D7E650DB Q36280711-2D4D9E7F-00A1-4090-8FED-082C5DBB1024 Q36521314-0E604468-D8F7-455D-87F9-BAD65C431B73 Q37004918-05578529-A1D1-4C81-8E39-F4D379D6FAC3 Q37213837-67BD8273-FAFA-4783-8AB2-2064E4893375

P2860

The role of BRAF V600 mutation in melanoma

http://www.wikidata.org/entity/Q34637951

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

The role of BRAF V600 mutation in melanoma

@ast

The role of BRAF V600 mutation in melanoma

@en

The role of BRAF V600 mutation in melanoma

@nl

type

label

The role of BRAF V600 mutation in melanoma

@ast

The role of BRAF V600 mutation in melanoma

@en

The role of BRAF V600 mutation in melanoma

@nl

prefLabel

The role of BRAF V600 mutation in melanoma

@ast

The role of BRAF V600 mutation in melanoma

@en

The role of BRAF V600 mutation in melanoma

@nl

P1433

Q34637951-AF1E9CFC-97E0-40CE-A556-2C14492E67A2

P1476

Q34637951-494C0033-EBB0-48D8-B413-297268FFE475

P2093

Q34637951-0E623F32-7FC5-41D8-87F6-EA1E33BF83B3

Q34637951-3D0555E9-ABC2-4AC1-A537-96C3057A3E95

Q34637951-66EB6336-1593-4D92-AC89-896F71E8F0C0

Q34637951-AC200DE7-271B-487A-94B6-DCCA02A35AAF

Q34637951-EB45B2C5-0563-4B38-B067-D2D131E95C7C

P2860

Q34637951-0831EE32-0B85-4B9B-9B09-65630EEE0771

Q34637951-08DFC943-D347-4DEE-BCCF-159A0B7B0C4A

Q34637951-0F6AFD7C-4A47-4C66-874A-CC587F794AD9

Q34637951-16A84146-9403-463E-A0CF-C5AACC33BF21

Q34637951-17AC9917-BEBB-4A2C-8408-49C97FF286AF

Q34637951-237E2720-4F3C-4DC4-9508-A353A5BD96F4

Q34637951-3813A5DA-7C0F-47B7-A755-A7B2E003EF44

Q34637951-395E7165-B877-4E01-89DD-2CE59218A9BC

Q34637951-3D9A8752-9E5F-4983-8452-69693BB8FBE8

Q34637951-409680F2-751D-4FB0-9A48-E7613510A521

P2888

Q34637951-4BCC8C7A-948A-4372-8D6D-0C3BCC475BE4

P304

Q34637951-0E142E1B-76B9-46BA-8E24-60682523DF88

P31

Q34637951-06d5851e-f425-4725-9e0f-19f27967351c

Q34637951-E5826798-DC54-44F7-9A76-32774140C350

P356

Q34637951-E1A162BF-4299-4B63-92EE-2B8193AD9CD6

P478

Q34637951-33FAFADC-EBF1-4A61-B43F-85B0C8A6F54B

P50

Q34637951-0F14BB4F-B990-4D95-863D-F6FDA23FE949

Q34637951-10442D85-E76D-4704-AA0B-CE1920B6EB81

Q34637951-69581152-8F1B-4FC1-8B4E-6EE6879B62B3

Q34637951-A5506656-3BAB-40E4-863C-4A89B22F3EF6

Q34637951-E3F51630-9162-40A5-A424-B5CA0433A993

P577

Q34637951-7CA147A8-FBBE-4B97-9DAB-096639B2EEEC

P5875

Q34637951-C2FBCB64-FFA4-4F49-8FD5-DCA2067F111E

P6179

Q34637951-C8E65FC8-7CEE-4971-BECB-C6A41E9C1DC6

P698

Q34637951-E347781F-E096-4AA5-B21D-005C09F56238

P932

Q34637951-CE55B2B9-F151-41F1-81E8-DD10C50BD91D

P356

1479-5876-10-85

P1433

Journal of Translational Medicine

P1476

The role of BRAF V600 mutation in melanoma

@en

P2093

Alessandro Testori

http://www.w3.org/2001/XMLSchema#string

Ester Simeone

http://www.w3.org/2001/XMLSchema#string

Francesco M Marincola

http://www.w3.org/2001/XMLSchema#string

John M Kirkwood

http://www.w3.org/2001/XMLSchema#string

Nicola Mozzillo

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

The Catalogue of Somatic Mutations in Cancer (COSMIC)

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

P2888

1479-5876-10-85

P304

85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-10-85

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Palmieri

Paolo Antonio Ascierto

Jean-Jacques Grob

Antonio M Grimaldi

P577

2012-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224895459

http://www.w3.org/2001/XMLSchema#string

P6179

1050474099

http://www.w3.org/2001/XMLSchema#string

P698

22554099

http://www.w3.org/2001/XMLSchema#string

P932

3391993

http://www.w3.org/2001/XMLSchema#string